Evidence map›Paper›PMID 27143278›Full record

ArticleScientific reports2016

Absence of NMDA receptor antibodies in the rare association between Type 1 Narcolepsy and Psychosis.

Y Dauvilliers, C Gaig, L Barateau, F Graus, A Iranzo, R Lopez, J Santamaria

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Narcolepsy and psychosis: A systematic review.Acta psychiatrica Scandinavica · 2021
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Narcolepsy and emotional experience: a review of the literature.Behavioral and brain functions : BBF · 2018
    Review
  6. Hypersomnolence, Hypersomnia, and Mood Disorders.Current psychiatry reports · 2017
    Review
  7. Article
  8. Narcolepsy and psychiatric comorbidity: a review of the literature.International journal of clinical and health psychology : IJCHP
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Y DauvilliersNational Reference Centre for Narcolepsy, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac, CHU Montpellier, France.
C GaigInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
L BarateauNational Reference Centre for Narcolepsy, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac, CHU Montpellier, France.
F GrausInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
A IranzoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
R LopezNational Reference Centre for Narcolepsy, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac, CHU Montpellier, France.
J SantamariaInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversité de Montpellier · FRHôpital Gui de Chauliac · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frequency and mechanisms underlying the association between narcolepsy type 1 (NT1) and psychosis remain unclear with potential role for a common immune pathway. We estimated the frequency of psychosis and its characteristics in NT1 at two European sleep centers (France, n = 381; Spain, n = 161) and measured IgG autoantibodies that recognize the GluN1 subunit of the NMDAR in 9 patients with NT1 with psychosis, and 25 NT1 patients without psychosis. Ten NT1 patients (6 in France, 4 in Spain) were diagnosed with comorbid psychosis, a frequency of 1.8%. One patient reported psychotic symptoms few months before narcolepsy onset, two patients few months after onset, and one patient one year after onset but after modafinil introduction. The six remaining patients reported long delays between NT1 and psychosis onset. Half the patients, mostly male adults, reported onset or worsening of psychotic symptoms after medication. We found no IgG antibodies to NR1/NR2B heteromers of the NMDARs in patients with NT1 with or without psychosis. To conclude, psychosis is rare in NT1, with limited evidence for a key impact of stimulants, and no association with anti-NMDAR antibodies. However, dramatic NT1 and schizophrenia exists especially in early onset NT1, which may lead to inappropriate diagnosis and management.

Indexed as

AutoantibodiesFemaleFranceHumansImmunoglobulin GMaleNarcolepsyPsychotic DisordersReceptors, N-Methyl-D-AspartateSpainAutoantibodiesImmunoglobulin GNR1 NMDA receptorNR2B NMDA receptorReceptors, N-Methyl-D-Aspartate

Identifiers

PMID27143278
PMCPMC4855232
OpenAlexW2346845726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.